Previous Article | Next Article ![]()
Molecular and Cellular Biology, January 2006, p. 502-512, Vol. 26, No. 2
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.2.502-512.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Howard Hughes Medical Institute,1 Department of Genetics and Tumor Cell Biology, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, Tennessee 381052
Received 9 August 2005/ Returned for modification 27 September 2005/ Accepted 18 October 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The best-characterized mechanism for initiating the p53 response is an intrinsic signal transduction cascade triggered by genotoxic stress. Different forms of DNA damage resulting from either single- or double-strand breaks, stalled replication forks, or exposure to cytotoxic drugs that affect DNA structure activate protein kinases of the ATM/ATR family (27). These, in turn, induce p53 phosphorylation both directly and through the agency of other kinases, such as Chk1 and Chk2, that are themselves activated through ATM/ATR phosphorylation (2). Phosphorylation of p53 at several sites near its N terminus not only interferes with its association with its negative regulator Mdm2 but also facilitates interactions between p53 and other transcriptional coactivators on p53-responsive promoters (27). Complexity stems from the fact that the p53 protein can undergo many posttranslational modifications including acetylation, sumoylation, and phosphorylation by many different kinases, all of which may contribute to its stability, activation state, and target specificity (5). Apart from the DNA damage response, aberrant growth-promoting signals emanating from oncogenes can also activate p53 by inducing the tumor suppressor, p19Arf (p14ARF in humans), which binds to Mdm2 and antagonizes its E3 ubiquitin ligase activity (40). Several other proteins, including the ribosomal proteins L11 and L23 and the nucleolar protein nucleophosmin (NPM/B23), have been reported to similarly contribute to the p53 response by inhibiting Mdm2 function (25, 34, 39, 62) and, like p53, Mdm2 can itself undergo regulatory phosphorylation that influences its interaction with p53 following different forms of oncogenic stress (44, 50).
In studying the genome-wide transcriptional response to p19Arf induction (33), we noted that the so-called hematopoietic zinc finger gene (Hzf) was induced with kinetics similar to Mdm2 and Cip1. Hzf was originally identified as a gene whose expression is induced in hematopoietic progenitor cells derived from differentiating embryonic stem cells in vitro (23). Although its elimination in the mouse germ line suggested a possible role for Hzf in late megakaryocytic differentiation, mice lacking the gene seemed to be otherwise normal (29). Here we show that Hzf is a bona fide transcriptional target of p53 that contributes to the maintenance of checkpoint arrest in cells responding to DNA damage.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Virus production and infection. 293T cells were transfected with retroviral expression plasmids expressing the designated genes of interest together with either green fluorescent protein or drug resistance markers in cis as previously described (64). Replication-defective viruses rescued with plasmids encoding requisite helper functions were harvested 24 to 60 h after transfection, pooled, and stored on ice. Exponentially growing cells in 10-cm-diameter culture dishes were infected with 3 ml of fresh virus-containing supernatant in complete medium containing 8 µg/ml polybrene (Sigma Chemicals, St. Louis, MO). Infection was confirmed either by flow cytometric assay for green fluorescent protein expression or by selection for drug resistance.
Hzf expression plasmids. Mouse Hzf cDNA was cloned from a mouse embryo (embryonic day 12 [E12]) cDNA library by PCR using the following primers: sense, 5'-AAAGAATTCATCCTCGGCAGCCTGAGCCG-3'; antisense, 5'-AAACTCGAGTCAGTAGGGGGAGAAGAGGA-3'. The PCR product, recloned and verified by nucleotide sequence analysis, was digested with EcoRI and XhoI and cloned into an mouse stem cell virus vector 3' to sequences specifying a Flag epitope (4). Hzf deletion mutant cDNAs were obtained by PCR using full-length Hzf cDNA as a template. Four PCRs were performed as follows: fragment A, Hzf sense and dZn-1AS (5'-CTCTTCGGGCGGAAATGACTGGCCGCTTGG-3'); fragment B, dZn-1S (5'-AGTCATTTCCGCCCGAAGAGTCAAAGGCAT-3') and Hzf antisense; fragment C, dZn-1S and dZn-2AS (5'-CGCCATCTCGGTAGAGCAGACGCTTAGCCT-3'); and fragment D, dZn-2S (5'-TCTGCTCTACCGAGATGGCGTGGCTGGGAA-3') and Hzf antisense. Purified PCR products were mixed (fragments A and B for the d2 mutant and fragments A, C, and D for the d3 mutant) and subjected to a second PCR using Hzf sense and antisense primers. For the knock-down of endogenous Hzf, annealed oligonucleotides (GATCCCCAGCCATGTCCATCCAACCCTTCAAGAGAGGGTTGGATGGACATGGCTTTTTTGGAAA and AGCTTTTCCAAAAAAGCCATGTCCATCCAACCCTCTCTTGAAGGGTTGGATGGACATGGCTGGG) were cloned into a pSUPERretro vector plasmid (Oligoengine, Seattle, WA) in accordance with the manufacturer's instructions.
Northern blotting. Total RNA prepared from NIH 3T3 and MT-Arf cells was separated on a 1% formaldehyde-agarose gel (20 µg/lane) and transferred to a Hybond-N+ membrane. Prehybridization, hybridization, and washing were performed as previously described (11). For detection by reverse transcription-PCR (RT-PCR), total RNA was reverse transcribed using a random oligohexamer primer and murine leukemia virus reverse transcriptase (Stratagene, La Jolla, CA). Reverse-transcribed products were aliquoted and subjected to PCR using the following primers: Hzf-sense, 5'-CCATCAAAGCTTACCCTCGG-3'; Hzf-antisense, 5'-AGAAGAGGATGGGTCCGTGC-3'; HPRT-sense, 5'-CCAGCAAGCCTTGCAACCTTAACCA-3'; and HPRT-antisense, 5'-GTAATGATCAGTCAACGGGGGAC-3' (HPRT is hypoxanthine phosphoribosyltransferase). Each of 25 cycles consisted of denaturation at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 1 min. The PCR products were separated on agarose gels, visualized by ethidium bromide, and subjected to Southern blotting using a full-length Hzf cDNA coding sequence as the probe.
Immunofluorescence and immunoblotting. An Hzf C-terminal peptide (LHPAPGPIRTAHGPILFSPY) conjugated to keyhole limpet hemocyanin was used to immunize rabbits, and antibodies were affinity purified, all as previously described (14). Cells on coverslips were fixed with 4% paraformaldehyde in phosphate-buffered saline for 10 min at room temperature and stained with affinity-purified antibodies to the Hzf C terminus for 1 h at room temperature. Washed coverslips were incubated with Texas Red-conjugated antibodies to rabbit immunoglobulin G (Amersham Biosciences, Piscataway, NJ). Cell lysates prepared in radioimmunoprecipitation assay buffer (1.25% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 150 mM NaCl, 10 mM sodium phosphate pH 7.2, 2 mM EDTA, 50 mM sodium fluoride, 0.2 mM sodium vanadate, 100 U/ml aprotinin) were separated by electrophoresis on polyacrylamide gels containing SDS and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). Proteins were detected using antibodies to the Hzf C terminus, p53 (Ab-7; Oncogene Research Products, Boston, MA), p21Cip1 (C-19; Santa Cruz Biotechnology, Santa Cruz, CA), CDK4 (C-22; Santa Cruz), and Mdm2 (2A10). Sites of antibody binding were detected using horseradish peroxidase-conjugated antibodies to mouse or rabbit immunoglobulin G as previously described (64).
Luciferase reporter assay. The annealed oligonucleotides (wild-type sense, 5'-TCTCCGCAGCCATCCTGCCCCGACACGCCGGGACCTGCCCCTCT CTCCCTGCGCCGGCT-3'; wild-type antisense, 5'-GATCAGCCGGCGCAGGGAGAGAGGGGCAGGTCCCGGCGTGTCGGGGCAGGATGGCTGCGGAGAGTAC-3'; mutant sense, 5'-TCTCCGCAGCCATCCTGCCCCGACACTAAGGGACCTTAACCTCTCTCCCTGCGCCGGCT-3'; and mutant antisense, 5'-GATCAGCCGGCGCAGGGAGAGAGGTTAAGGTCCCTTAGTGTCGGGGCAGGATGGCTGCGGAGAGTAC-3') were inserted into KpnI/BglII sites of a pGl2-Promoter vector (Promega, Madison, WI) and transfected into NIH 3T3 cells (5 x 104 cells per 3.5-cm diameter culture dish) together with pRL-SV40 (where SV40 is simian virus 40; Promega) in the presence or absence of a p19Arf expression plasmid. Cell lysates were prepared 48 h later, and luciferase activities were measured using a dual luciferase reporter assay system (Promega). For the measurement of ionizing radiation (IR)-induced luciferase activity, cells were irradiated 12 h before lysate preparation. Luciferase (firefly) activity in each sample was normalized by Renilla luciferase.
Electrophoretic mobility shift assay (EMSA).
Annealed oligonucleotides (wild-type sense, 5'-TTTCATCCTGCCCCGACACGCCGGGACCTGCCCCTCTCTCCCT-3'; wild-type antisense, 5'-TTTAGGGAGAGAGGGGCAGGTCCCGGCGTGTCGGGGCAGGATG-3'; mutant sense, 5'-TTTCATCCTGCCCCGACACTAAGGGACCTTAACCTCTCTCCCT-3'; and mutant antisense, 5'-TTTAGGGAGAGAGGTTAAGGTCCCTTAGTGTCGGGGCAGGATG-3') were radiolabeled using Klenow fragment (New England Biolabs, Beverly, MA) and [
-32P]dATP (6,000 Ci/mmol; Perkin Elmer Life Sciences, Boston, MA). p53 protein was produced by in vitro transcription/translation using a rabbit reticulocyte lysate system (Promega) and preincubated at room temperature for 15 min in buffer containing 20 mM HEPES (pH 7.9), 50 mM KCl, 5 mM MgCl2, 10 mM ZnSO4, 0.2% NP-40, 10% glycerol, 1 mM spermidine, 0.1 mg/ml bovine serum albumin, 0.5 mM dithiothreitol, and 10 ng/µl poly(dI-dC) in the presence or absence of 1 µg of p53 antibody (PAb421 [Oncogene Research Products] and DO-1 [Santa Cruz], respectively). Radiolabeled probe (104 cpm per sample) was then added and incubated for 15 min at room temperature; samples were electrophoretically separated on 4% polyacrylamide gels containing 22.5 mM Tris-borate and 0.5 mM EDTA, and complexes were detected by autoradiography.
ChIP. Chromatin immunoprecipitation (ChIP) was performed by a modified protocol (22) using p53-null MEFs infected with control or human p53-expressing retroviruses. A total of 107 cells used for each immunoprecipitation were cross-linked in 1% formaldehyde for 10 min and then neutralized with 0.125 M glycine. Cells were scraped, washed with phosphate-buffered saline, resuspended in cell lysis buffer I (10 mM HEPES, pH 6.5, 10 mM EDTA, 0.5 mM EGTA, 0.25% Triton X-100, and protease inhibitors), and incubated on ice for 10 min. Cells were then collected by centrifugation and resuspended in cell lysis buffer II (10 mM HEPES, pH 6.5, 1 mM EDTA, 0.5 mM EGTA, 0.2 M NaCl, and protease inhibitors). Nuclei were precipitated and suspended (0.3 ml for each immunoprecipitation reaction) in nuclei lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, and protease inhibitors) and sonicated 10 times for 15 s to yield genomic DNA 200 to 600 base pairs in length. Sonicated chromatin was diluted to 1 ml with immunoprecipitation dilution buffer (1% Triton X-100, 2 mM EDTA, 20 mM Tris-Cl, pH 8.1, and 150 mM NaCl) and precleared with salmon sperm DNA-coated protein A beads (Upstate, Charlottesville, CA) twice for 90 min. Precleared lysates were then immunoprecipitated overnight at 4°C with 1 µg of anti-p53 antibody FL-393 (Santa Cruz) or PAb421. Immune complexes recovered after incubation with protein A beads for 3 h were washed seven times with immunoprecipitation wash buffer (50 mM HEPES, pH 7.6, 1 mM EDTA, 0.7% deoxycholic acid, 0.5 M LiCl, 1% NP-40, and protease inhibitors) and once with Tris-EDTA buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Beads were rotated for 3 min at 4°C between each washing step. Immune complexes were eluted twice for 15 min with 0.1 ml of elution buffer (0.1 M NaHCO3 and 1% SDS) and incubated with 10 µg of RNase A for 60 min at 37°C, followed by treatment with 4 µg of proteinase K at 42°C for 150 min. Immune complexes were incubated at 65°C overnight to reverse formaldehyde cross-links, and genomic DNA was isolated with a PCR purification kit (QIAGEN, Valencia, CA) and subjected to PCR (35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 1 min) using the following Hzf primers: sense, 5'-AGATGCTGGGTGTAGCTTCG-3'; antisense, 5'-CCACTCTGACTTTCCTTCTC-3'). As a positive control, the Cip1 gene was similarly amplified using the following primers: sense, 5'-CCAGAGGATACCTTGCAAGGC-3'; and antisense, (5'-TCTCTGTCTCCATTCATGCTCCTCC-3'.
Fluorescence-activated cell sorting (FACS) analysis. Cells seeded at subconfluent density were pulse labeled with 10 µM bromodeoxyuridine (BrdU) for 30 min and exposed to 15 Gy of gamma irradiation. Irradiated cells were collected at the indicated times and stained with fluorescein isothiocyanate-conjugated antibody to BrdU and 7-amino-actinomycin D using a fluorescein isothiocyanate-BrdU Flow kit (BD Biosciences, San Diego, CA). Stained cells were analyzed using a FACSCaliber sorter (BD Biosciences).
Ubiquitination assay for p21Cip1 protein. NIH 3T3 cells were transfected with 0.1 µg of Flag-p21, 1 µg of shHzf, and 2 µg of His-ubiquitin expression plasmids using Fugene 6 (Roche, Indianapolis, IN). His-ubiquitinated proteins were purified under denaturing conditions as described previously (32). Cells were suspended in lysis buffer containing 8 M urea, 0.1 M NaHPO4, 10 mM Tris-Cl, pH 8.0, 10 mM imidazole, 10% glycerol, 0.1% Triton X-100, 0.5 M NaCl, and 10 mM ß-mercaptoethanol and sonicated for 15 s, and lysates were cleared by centrifugation. Cleared lysates were incubated with Ni-nitrilotriacetic acid agarose beads (QIAGEN) at room temperature for 6 h. Beads were washed five times with lysis buffer and boiled in denaturing gel sample buffer containing 0.2 M imidazole, and eluted proteins were separated on denaturing gels and subjected to immunoblotting.
| RESULTS |
|---|
|
|
|---|
To confirm that Hzf mRNA is induced by p19Arf, RNAs prepared from control Arf-null NIH 3T3 cells and from a zinc-inducible derivative in which the metallothionein promoter regulates an Arf transgene (MT-Arf) were analyzed by Northern blotting using the Hzf cDNA as a probe. In this inducible system, p19Arf protein is first detected within 4 h after the addition of zinc sulfate to the medium, after which p53 and p53-induced proteins such as Mdm2 or p21Cip1 accumulate; the cells withdraw completely from the division cycle within 24 h, arresting in both the G1 and G2 phases (33). Hzf and Mdm2 mRNAs accumulated de novo in MT-Arf cells, but not in control NIH 3T3 cells, within 8 h after the addition of zinc sulfate (Fig. 1A). Using antibodies directed to the predicted C terminus of Hzf, we observed accumulation of the protein predominantly within nuclei of induced MT-Arf cells (Fig. 1B). Since p53 can be activated in a p19Arf-independent manner by many genotoxic stresses, we exposed NIH 3T3 cells to IR and determined that both Hzf mRNA and protein were again rapidly induced (Fig. 1C). Together, these results raised the possibility that Hzf might be a direct target of p53-mediated transcription.
|
|
Hzf overexpression leads to tetraploidization, checkpoint failure, and cell death.
To address the biological activity of Hzf, we used retroviral vectors to enforce expression of the exogenous Hzf protein or of mutants lacking two (d2) or three (d3) zinc fingers (Fig. 3A). Overexpression of Hzf inhibited colony formation in both NIH 3T3 cells and in p53-null MEFs, suggesting that Hzf itself has p53-independent antiproliferative activity (Fig. 3B), whereas the mutants were without effect (data not shown). When analyzed 3 days after infection, many Hzf-transduced cells exhibited a 4N DNA content; in contrast, cells infected with vectors encoding the two Hzf deletion mutants were not significantly affected (Fig. 3C). Microscopic inspection of fixed and stained cells indicated that many of those transduced with wild-type Hzf became binucleate (Fig. 3D); in turn, staining with antibodies to
-tubulin revealed that more than half of this population contained greater than two centrosomes (Fig. 3E). Despite the increased number of cells with 4N DNA content, subsequent biochemical analyses indicated that the Hzf-transduced population exhibited very low levels of mitotic cyclins A and B and cyclin A-dependent histone H1 kinase activity, whereas cyclins D1 and E were readily detected (data not shown). Together, these data imply that cells engineered to overexpress Hzf undergo an abortive mitosis, return to a G1 state without undergoing cytokinesis, and thereby become tetraploid and exhibit additional centrosomes. If their p53-dependent checkpoint is intact, such cells should arrest in G1 (35, 43, 45, 48). However, we noted that many such cells continued to incorporate BrdU for several more days (Fig. 3G), and this concomitantly led to cell death (Fig. 3H). Immunofluorescence staining with antibodies to
-tubulin (Fig. 3F) and centriolin (not shown) further revealed that many such cells exhibited more than four centrosomes despite the absence of detectable 8N DNA content, indicating that the centrosome and DNA replication cycles had been uncoupled. Therefore, although NIH 3T3 cells retain wild-type p53 and can mount a robust p53 transcriptional response (see above), p53-dependent checkpoints fail when Hzf expression is enforced, and the cells form extranumerary centrosomes, reenter S phase, and ultimately die.
|
|
|
Hzf is required for accumulation of the p21Cip1 protein after DNA damage. To explain the effects of Hzf loss on the cellular response to IR, we surveyed the expression of several cell cycle regulators that have been implicated in maintaining the G2 checkpoint (9, 58). Chief among these are the Cdc25 family proteins required for mitotic entry that are down-regulated by several DNA damage signaling molecules, including p53 (41, 54). We first compared the protein levels of Cdc25A, Cdc25B, and Cdc25C in control and Hzf knockdown cells after IR but did not note significant effects of Hzf loss of function on their expression. Whereas Cdc25B levels remained constant, Cdc25A and Cdc25C were reduced to undetectable levels after IR, whether cells were exposed to shHzf RNA or not (data not shown), in agreement with previous observations that their turnover is increased in response to DNA damage (2).
By contrast, induction of p21Cip1 by IR was significantly diminished in shHzf knockdown cells (Fig. 5A, lanes 9 to 12) versus its levels in cells infected with a control virus (lanes 1 to 4). Note that in response to IR treatment, the Hzf and p53 proteins were induced prior to the accumulation of p21Cip1 (lanes 1 to 4), whereas introduction of shRNA to Hzf reduced the levels of the Hzf and p21Cip1 proteins without affecting that of p53 (lanes 9 to 12). Moreover, shHzf RNA did not affect the p53-mediated induction of Mdm2, so p53 activity per se was not attenuated in Hzf knockdown cells after DNA damage.
To verify that the defect in p21Cip1 induction could be attributed to the loss of Hzf protein but not to off-target effects caused by the shHzf RNA, Flag-tagged Hzf proteins were reintroduced into the knockdown cells. Under the conditions used, the reprogrammed level of the exogenous Flag-tagged Hzf protein was comparable to that of the endogenous protein; due to the absence of the 3' untranslated region target sequence in the Flag-Hzf construct, its expression was not affected by the shHzf interfering RNA (Fig. 5A, top panel, lanes 5 to 8 and 13 to 16). By contrast, shHzf RNA again reduced the level of the endogenous Hzf protein, which migrated faster than Flag-Hzf on the denaturing gels. The presence of the Flag-tagged Hzf protein did not affect basal p21Cip1 expression in nonirradiated control cells or markedly increase its level after radiation treatment (compare lanes 1 to 4 and 5 to 8). However, introduction of the Flag-Hzf protein restored IR induction of p21Cip1 in cells expressing shHzf (lanes 13 to 16 versus lanes 9 to 12). We next tested whether the Hzf d2 mutant previously shown to be defective in inducing Hzf-mediated phenotypes would rescue the inhibitory effects of shHzf on IR induction of p21Cip1. While in this case the levels of enforced expression of Flag-tagged Hzf proteins eclipsed that of endogenous Hzf, the Flag-Hzf d2 mutant was unable to restore Hzf function (Fig. 5B, lanes 16 to 18 versus lanes 13 to 15). Therefore, Hzf is required for the efficient accumulation of p21Cip1 following IR exposure. These results are consistent with a previous demonstration that the p53-p21Cip1 pathway is required for sustained G2 arrest after DNA damage, although it is not essential for its initiation (7, 58).
Because p53-dependent expression of p21Cip1 can prevent irradiated G1 phase cells from entering S phase (6, 12, 16, 20, 59), we further explored the effects of shHzf on irradiated cells stimulated to reenter the division cycle from quiescence. Confluent cultures of shHzf knockdown cells or of cells expressing the control vector were starved of serum. After 24 h, the cells were trypsinized, replated at a lower density, and stimulated with serum to reenter G1 phase synchronously. Stimulated cells were exposed to various doses of ionizing radiation, and their DNA content was measured both 12 and 18 h after mitogenic stimulation. Although shHzf treatment significantly diminished the levels of p21Cip1 induced in response to all doses of IR tested (see Fig. S1A in the supplemental material), both control and shHzf-treated cells retained an intact G1 checkpoint response (see Fig. S1B in the supplemental material). Evidently, the residual amount of p21Cip1 expressed in irradiated shHzf-treated cells was still adequate to inhibit entry into S phase.
Hzf loss does not affect the transcription of Cip1 but accelerates p21Cip1 turnover. Expression of p21Cip1 is regulated at both the transcriptional and posttranslational level. Cip1 mRNA levels, as well as those of other canonical p53 target genes including cyclin G1 and Mdm2, were increased after IR in both control and Hzf knockdown cells, indicating that Hzf loss does not interfere at a detectable level with p53-mediated transcriptional activation of these target genes (Fig. 6A). The half-life of the p21Cip1 protein was also similar in nonirradiated control NIH 3T3 and Hzf knockdown cells, respectively (Fig. 6B and C). Whereas IR treatment did not alter p21Cip1 protein stability in control cells, its half-life was markedly reduced in irradiated Hzf knockdown cells (Fig. 6B and C). Therefore, the defect in p21Cip1 protein accumulation after IR in Hzf knockdown cells is due to its increased turnover.
|
|
| DISCUSSION |
|---|
|
|
|---|
-granules, and the animals otherwise appear to be overtly normal (23, 29). The limited role of Hzf in hematopoiesis is likely to be independent of p53, since no such phenotype has been described in p53-null mice, which have been scrupulously analyzed by many laboratories. The Hzf protein localizes to the nucleoplasm and contains three typical C2H2-type zinc finger domains that can potentially serve as nucleic acid-binding motifs. However, Rzf, the human orthologue of Hzf, does not bind to single- or double-stranded nucleic acids in vitro and appears not to act as a transcription factor (51). Thus, the biochemical function of the Hzf protein remains unknown. We have now found that Hzf is a direct transcriptional target of the p53 tumor suppressor. Hzf is induced by ionizing radiation or via the Arf tumor suppressor pathway with kinetics similar to those of other p53-responsive genes, whereas its induction by these stimuli did not occur in cells lacking functional p53. A promoter-reporter plasmid containing a putative p53 enhancer sequence derived from the first intron of the Hzf gene responded to p53. EMSAs revealed that p53 could bind directly to the putative enhancer element but not to mutated consensus sequences, and ChIP experiments confirmed that p53 can bind directly to this intronic sequence in living cells. Conversely, shRNA-mediated reduction of Hzf did not affect the p53-dependent transcriptional activation of Cip1 or Mdm2 after DNA damage, so Hzf functions "downstream" of p53 and is itself not involved in regulating p53 activity per se. Together, these findings imply that Hzf can act to regulate p53-directed responses to DNA damage and oncogene activation, which can adversely affect genome integrity.
Several lines of evidence suggest that Hzf plays a role in cell cycle checkpoint control. Overexpression of the Hzf protein led to an accumulation of tetraploid cells, some of which were binuclear; these cells contained extranumerary centrosomes, continued to cycle, and ultimately died. Similar events have been observed when functions of key regulators of mitotic entry or exit are compromised, resulting from debilitating mutations affecting a wide spectrum of genes that regulate G2 checkpoint arrest, mitotic progression, the spindle checkpoint, kinetochore and centrosome integrity, and cytokinesis (8, 15, 17, 24, 28, 35, 37, 42, 48, 53, 57, 58, 60, 63). Like cells that overexpress Hzf, those that fail to undergo mitosis for other reasons become tetraploid, contain twice their normal complement of centrosomes, and revert to a G1 state in which the mitotic cyclins A and B are no longer expressed and are replaced by cyclins D and E. Unless p53 function is disrupted, such cells arrest in G1 phase (1, 15, 35, 43, 48). Possibly, alterations in centrosome composition coupled with a p53-dependent reduction in cyclin E-dependent Cdk activity prevent further centrosome duplication as well as the reinitiation of DNA synthesis (15). However, if p53 function is disabled, such cells reenter S phase, acquire even more centrosomes, and advance into mitosis with multipolar spindles, leading to abortive divisions and cell death. Notably, Hzf can prevent colony formation both in p53-positive fibroblasts as well as in primary p53-null MEFs, so its effects must be at least partially p53 independent. How overexpression of Hzf triggers the accumulation of tetraploid cells that bypass the p53-dependent G1 checkpoint and continue to cycle remains a mystery.
We obtained some mechanistic insights from loss-of-function experiments performed using shRNAs directed to Hzf. Knock-down of endogenous Hzf by shRNA limited the duration of G2 phase arrest following DNA damage, and these cells exhibited increased radiosensitivity. Cdc25A and Cdc25C levels fell dramatically after shHzf-treated cells were exposed to ionizing radiation, but p21Cip1 did not efficiently accumulate to expected levels. This suggested that Hzf regulates the level of p21Cip1 following irradiation of cells, in agreement with observations that Cip1-null cells are defective in maintaining G2 cell cycle arrest triggered by DNA damage and are more sensitive to DNA-damaging agents (7, 9, 58). Therefore, we reason that the failure of p21Cip1 to accumulate under these conditions could contribute to the impaired G2 arrest and to the increased radiosensitivity of Hzf knock-down cells. In contrast, when Hzf knock-down cells were stimulated to synchronously enter the cell cycle from quiescence and were then exposed to IR early in G1 phase, the observed reduction in p21Cip1 levels was not sufficient to allow entry into S phase. We cannot exclude the possibility, however, that an shHzf-mediated reduction of p21Cip1 in continuously cycling cells might blunt G1 arrest.
In unstressed cells "basal" ubiquitination of p21Cip1 seems not to be required for its proteasome-dependent degradation (3, 10, 52, 56), as nonubiquitinated p21Cip1 is degraded by the proteasome as efficiently both in vitro (38) and in vivo (52). Other investigators have reported that UV irradiation regulates ubiquitin-dependent degradation of p21Cip1 (3). In turn, our findings revealed that Hzf suppression can increase the ubiquitination and turnover of p21Cip1. Therefore, we presume that p53-induced Hzf can protect the p21Cip1 protein from ubiquitination and facilitate its accumulation in response to DNA damage.
However, we think it likely that Hzf affects the activity of proteins other than p21Cip1. First, Hzf overexpression causes phenotypic changes without affecting p21Cip1 expression at a detectable level, and it also does so in p53-null cells that express very low levels of p21Cip1. Second, when shRNAs directed to p21Cip1 were used, the attenuation of G2 arrest following IR treatment was less than that observed in cells treated with shHzf (data not shown), whereas inactivation of p21Cip1 more strongly compromises the G1 checkpoint (12, 20, 59). The simplest idea is that Hzf's effects might be mediated through the ubiquitin-proteasome pathway and involve several targets, p21Cip1 among them.
How does the absence of Hzf increase p21Cip1 ubiquitination and degradation? We have not detected a direct physical interaction between Hzf and p21Cip1 in cells, nor have we observed an effect of Hzf loss on the localization of p21Cip1 in cells before or after DNA damage. A yeast two-hybrid interactive screen using Hzf as bait identified APC5, a component of the anaphase-promoting (E3 ligase) complex as a protein that can physically interact with Hzf but not with the Hzf d2 mutant (M. Sugimoto, unpublished). However, we have so far been unable to implicate Hzf as a bona fide regulator of the anaphase-promoting complex in vivo. Whatever the exact mechanisms, our results indicate that Hzf and p21Cip1, both p53 targets, act in concert to coordinate the p53 response upon DNA damage.
| ACKNOWLEDGMENTS |
|---|
This work was supported in part by NCI Cancer Center Core Grant CA-21765 and by ALSAC of St. Jude Children's Research Hospital. C.J.S. is an Investigator of the Howard Hughes Medical Institute.
| FOOTNOTES |
|---|
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Bartek, J., and J. Lukas. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429.[CrossRef][Medline]
3. Bendjennat, M., J. Boulaire, T. Jascur, H. Brickner, V. Barbier, A. Sarasin, A. Fotedar, and R. Fotedar. 2003. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 114:599-610.[CrossRef][Medline]
4. Bertwistle, D., M. Sugimoto, and C. J. Sherr. 2004. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24:985-996.
5. Brooks, C. L., and W. Gu. 2003. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15:164-171.[CrossRef][Medline]
6. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.[CrossRef][Medline]
7. Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
8. Carroll, P. E., M. Okuda, H. F. Horn, P. Biddinger, P. J. Stambrook, L. L. Gleich, Y.-Q. Li, P. Tarapore, and K. Fukasawa. 1999. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18:1935-1944.[CrossRef][Medline]
9. Chan, T. A., P. M. Hwang, H. Hermeking, K. W. Kinzler, and B. Vogelstein. 2000. Cooperative effects of genes controlling the G2/M checkpoint. Genes Dev. 14:1584-1588.
10. Chen, X., Y. Chi, A. Bloecher, R. Aebersold, B. E. Clurman, and J. M. Roberts. 2004. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol. Cell 16:839-847.[CrossRef][Medline]
11. Church, G. M., and W. Gilbert. 1984. Genomic sequencing. Proc. Natl. Acad. Sci. USA 81:1991-1995.
12. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21Cip1/Waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684.[CrossRef][Medline]
13. De Stanchina, E., E. Querido, M. Narita, R. V. Davuluri, P. P. Pandolfi, G. Ferbeyre, and S. W. Lowe. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13:523-535.[CrossRef][Medline]
14. Downing, J. R., S. A. Shurtleff, and C. J. Sherr. 1991. Peptide antisera to human colony-stimulating factor 1 receptor detect ligand-induced conformational changes and a binding site for phosphatidylinositol 3-kinase. Mol. Cell. Biol. 11:2489-2495.
15. Doxsey, S., W. Zimmerman, and K. Mikule. 2005. Centrosome control of the cell cycle. Trends Cell Biol. 15:303-311.[CrossRef][Medline]
16. El-Deiry, W. S., T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, E. Mercer, K. W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.[CrossRef][Medline]
17. Fukusawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747.[Abstract]
18. Funk, W. D., D. T. Pak, R. H. Karas, W. E. Wright, and J. W. Shay. 1992. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12:2866-2871.
19. Hainaut, P., T. Soussi, B. Shomer, M. Hollstein, M. Greenblatt, E. Hovig, C. C. Harris, and R. Montesano. 1997. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25:151-157.
20. Harper, J. W., G. R. Adami, N. Wei, K. Keyomarsi, and S. J. Elledge. 1993. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816.[CrossRef][Medline]
21. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.[CrossRef][Medline]
22. Hershko, T., and D. Ginsberg. 2004. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J. Biol. Chem. 279:8627-8634.
23. Hidaka, M., G. Caruana, W. L. Stanford, M. Sam, P. H. Correll, and A. Bernstein. 2000. Gene trapping of two novel genes, Hzf and Hh1, expressed in hematopoietic cells. Mech. Dev. 90:3-15.[CrossRef][Medline]
24. Hollander, M. C., M. S. Sheikh, D. V. Bulavin, K. Lundgren, L. Augeri-Henmueller, R. Shehee, T. A. Molinaro, K. E. Kim, E. Tolosa, J. D. Ashwell, M. P. Ronsenberg, Q. Zhan, P. M. Fernandez-Salguero, W. F. Morgan, C. X. Deng, and A. J. Jr. Fornace. 1999. Genomic instability in Gadd45a-deficient mice. Nat. Genet. 23:176-184.[CrossRef][Medline]
25. Jin, A., K. Itahana, K. O'Keefe, and Y. Zhang. 2004. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol. Cell. Biol. 24:7669-7680.
26. Juven, T., Y. Barak, A. Zauberman, D. L. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the Mdm2 gene. Oncogene 8:3411-3416.[Medline]
27. Kastan, M. B., and J. Bartek. 2004. Cell cycle checkpoints and cancer. Nature 432:316-323.[CrossRef][Medline]
28. Katayama, H., W. R. Brinkley, and S. Sen. 2003. The aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev. 22:451-464.[CrossRef][Medline]
29. Kimura, Y., A. Hart, M. Hirashima, C. Wang, D. Holmyard, J. Pittman, X. L. Pang, C. W. Jackson, and A. Bernstein. 2002. Zinc finger protein, Hzf, is required for megakaryocyte development and hemostasis. J. Exp. Med. 195:941-952.
30. Kriwacki, R. W., L. Hengst, L. Tennant, S. I. Reed, and P. E. Wright. 1996. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. Proc. Natl. Acad. Sci. USA 93:11504-11509.
31. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.[CrossRef][Medline]
32. Kuo, M.-L., W. den Besten, D. Bertwistle, M. F. Roussel, and C. J. Sherr. 2004. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18:1862-1874.
33. Kuo, M.-L., E. J. Duncavage, R. Mathew, W. den Besten, D. Pie, D. Naeve, T. Yamamoto, C. Cheng, C. J. Sherr, and M. F. Roussel. 2003. Arf induces p53-dependent and independent anti-proliferative genes. Cancer Res. 63:1046-1053.
34. Kurki, S., K. Peltonen, L. Latonen, T. M. Kiviharju, P. M. Ojala, D. Meek, and M. Laiho. 2004. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 5:465-475.[CrossRef][Medline]
35. Lanni, J. S., and T. Jacks. 1998. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18:1055-1064.
36. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.[CrossRef][Medline]
37. Li, F., E. J. Ackermann, C. F. Bennett, A. L. Rothermel, J. Plescia, S. Tognin, A. Villa, P. C. Marchisio, and D. C. Altieri. 1999. Pleiotropic cell division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1:461-466.[CrossRef][Medline]
38. Liu, C. W., M. J. Corboy, G. N. DeMartino, and P. J. Thomas. 2003. Endoproteolytic activity of the proteasome. Science 299:408-411.
39. Lohrum, M. A., R. L. Ludwig, M. H. Kubbutat, M. Hanlon, and K. H. Vousden. 2003. Regulation of HDM2 activity by ribosomal protein L11. Cancer Cell 3:577-587.[CrossRef][Medline]
40. Lowe, S. W., and C. J. Sherr. 2003. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13:77-83.[CrossRef][Medline]
41. Mailand, N., J. Falck, C. Lukas, R. G. Syljuasen, M. Welcker, J. Bartek, and J. Lukas. 2000. Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425-1429.
42. Mantel, C., S. E. Braun, S. Reid, O. Henegariu, L. Liu, G. Hangoc, and H. E. Broxmeyer. 1999. p21(cip-1/waf-1) deficiency causes deformed nuclear architecture, centriole overduplication, polyploidy, and relaxed microtubule damage checkpoints in human hematopoietic cells. Blood 93:1390-1398.
43. Margolis, R. L., O. D. Lohez, and P. R. Andreassen. 2003. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J. Cell Biochem. 88:673-683.[CrossRef][Medline]
44. Maya, R., M. Balass, S. T. Kim, D. Shkedy, J. F. Leal, O. Shifman, M. Moas, T. Buschmann, Z. Ronai, Y. Shiloh, M. B. Kastan, E. Katzir, and M. Oren. 2001. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15:1067-1077.
45. Meraldi, P., R. Honda, and E. A. Nigg. 2002. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53/ cells. EMBO J. 21:483-492.[CrossRef][Medline]
46. Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299.[CrossRef][Medline]
47. Nakano, K., and K. H. Vousden. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7:683-694.[CrossRef][Medline]
48. Nigg, E. A. 2002. Centrosome aberrations: cause or consequence of cancer progression? Nat. Rev. Cancer 2:815-825.[CrossRef][Medline]
49. Prives, C. 1998. Signaling to p53: breaking the MDM2-p53 circuit. Cell 95:5-8.[CrossRef][Medline]
50. Ries, S., C. Biederer, D. Woods, O. Shifman, S. Shirasawa, T. Sasazuki, M. McMahon, M. Oren, and F. McCormick. 2000. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103:321-330.[CrossRef][Medline]
51. Sharma, S., D. Dimasi, K. Higginson, and N. G. Della. 2004. RZF, a zinc-finger protein in the photoreceptors of human retina. Gene 342:219-229.[CrossRef][Medline]
52. Sheaff, R. J., J. D. Singer, J. Swanger, M. Smitherman, J. M. Roberts, and B. E. Clurman. 2000. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol. Cell 5:403-410.[CrossRef][Medline]
53. Smith, L., S. J. Liu, L. Goodrich, D. Jacobson, C. Degnin, N. Bentley, A. Carr, G. Flaggs, K. Keegan, M. Hoekstra, and M. J. Thayer. 1998. Duplication of ATR inhibits MyoD, induces aneuploidy, and eliminates radiation-induced G1 arrest. Nat. Genet. 19:39-46.[Medline]
54. St. Clair, S., L. Giono, S. Varmeh-Ziaie, L. Resnick-Silverman, W. J. Liu, A. Padi, J. Dastidar, A. DaCosta, M. Mattia, and J. J. Manfredi. 2004. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the Cdc25C promoter. Mol. Cell 16:725-736.[CrossRef][Medline]
55. Thornborrow, E. C., S. Patel, A. E. Mastropietro, E. M. Schwartzfarb, and J. J. Manfredi. 2002. A conserved intronic response element mediates direct p53-dependent transcriptional activation of both the human and murine Bax genes. Oncogene 21:990-999.[CrossRef][Medline]
56. Touitou, R., J. Richardson, S. Bose, M. Nakanishi, J. Rivett, and M. J. Allday. 2001. A degradation signal located in the C terminus of p21WAF1/CIP1 is a binding site for the C8
-subunit of the 20S proteasome. EMBO J. 20:2367-2375.[CrossRef][Medline]
57. Tutt, A., A. Gabriel, D. Bertwistle, F. Connor, H. Paterson, J. Peacock, G. Ross, and A. Ashworth. 1999. Absence of Brca2 causes genome instability by chromosome breakage and loss associated with centrosome amplification. Curr. Biol. 9:1107-1110.[CrossRef][Medline]
58. Waldman, T., C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716.[CrossRef][Medline]
59. Xiong, Y., G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704.[CrossRef][Medline]
60. Xu, X., Z. Weaver, S. P. Linke, C. Li, J. Gotay, X. W. Wang, C. C. Harris, T. Ried, and C. X. Deng. 1999. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell 3:389-395.[CrossRef][Medline]
61. Yu, J., L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7:673-682.[CrossRef][Medline]
62. Yuan, X., Y. Zhou, E. Casanova, M. Chai, E. Kiss, H. J. Grone, G. Schutz, and I. Grummt. 2005. Genetic inactivation of the transcription factor TIF-1A leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol. Cell 19:77-87.[CrossRef][Medline]
63. Zhou, H., J. Kuang, L. Zhong, W. L. Kuo, J. W. Gray, A. Sahin, B. R. Brinkley, and S. Sen. 1998. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy, and transformation. Nat. Genet. 20:189-193.[CrossRef][Medline]
64. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
| ||||||||||||||